Project Grant R41TR003752
Award Date
4/19/21
Completion Date
4/18/23
Dollars Obligated
$770K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Albany, CA 94710, USA
Similar Awards
Acrigen Biosciences, Inc. was awarded a $1,000,000 cooperative agreement from the National Science Foundation under the Engineering program (CFDA 47.041) to develop a curative gene therapy for spinal muscular atrophy. Over the two year period from March 2022 to February 2024, Acrigen will engineer an anti-CRISPR protein to increase the precision and safety of CRISPR-Cas gene editing. They will pair this with a novel CRISPR nuclease and validate the system for editing and disease correction in...
The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $100,000 will support research to develop next-generation clustered regularly interspaced short palindromic repeat (CRISPR) systems for curing inherited diseases. Specifically, the awardee, the University of California, Berkeley, will work to circumvent in vivo delivery challenges with CRISPR-Cas9 by developing miniature RNA-guided genome editors smaller than Cas9 that can be...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...
This Project Grant award of $240,039 from the National Institutes of Health's Office of Research Infrastructure Programs (CFDA 93.351 - Research Infrastructure Programs) supports the development of a novel mouse model for detecting genome editing events using CRISPR/Cas9 technology. The project aims to design and test a "single-hit" approach that utilizes Cre recombinase fused to an estrogen receptor ligand binding domain (ERT2) to provide a more sensitive system for detecting a...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director (CFDA 93.351 - Research Infrastructure Programs) will support the development of a modular system for mouse CRISPR genome and epigenome editing. The $222,500 award, effective May 15, 2025 through March 31, 2027, will enable researchers at Boston Children's Hospital to create transgenic mouse lines expressing core CRISPR-Cas9 platforms functionalized with protein ligation tags. This will allow more...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $339,999 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Couragene, Inc., a for-profit organization located in Edison, New Jersey. The grant supports the development of a novel, chemically modified ribonucleoprotein (CRNP) delivery system for CRISPR-based gene editing to treat Angelman syndrome, a neurogenetic disorder. The project aims to optimize...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to explore the feasibility and safety of using adeno-associated virus (AAV) gene therapy to restore fertility in mouse models of human non-obstructive azoospermia (NOA). The $192,056 award, effective August 12, 2024 through February 28, 2027, will allow the principal investigator to:...
The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), has awarded a $869,959 Cooperative Agreement to The Regents of the University of California, San Francisco to develop a safe and effective genome editing therapy to treat frontotemporal dementia caused by the C9ORF72 gene mutation. The project aims to optimize a CRISPR/Cas9 genome editing strategy to excise the C9ORF72 repeat...
This federal Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $383,748 to Jumpcode Genomics Inc. to develop a CRISPR-based depletion technology to resolve pseudogene contamination in next-generation sequencing (NGS)-based genetic testing, particularly for newborn screening (NBS) clinical tests. The key objectives are to computationally design CRISPR guide RNAs and optimize depletion protocols to remove pseudogene-derived...